Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Genpathway to Offer ChIP Sequencing, Assays and Analysis Service

NEW YORK (GenomeWeb News) – Illumina and Genpathway have partnered to offer scientists a solution for studying transcription factor binding and gene regulation in drug development research, Illumina said today.
 
Under the partnership, Genpathway will prepare samples using its FactorPath ChIP assays and will conduct data analysis using its software. The sequencing will be handled by Illumina’s Sequencing Services, which will employ the firm’s high-throughput Genome Analyzer, the company said.
 
The combined services the companies plan to offer include cell or tissue processing, antibody selection and qualification, and ChIP DNA amplification, Illumina said.
 
Because ChIP sequencing is “a notoriously time-consuming and difficult procedure,” Genpathway CSO Mary Harper said in a statement, the partnership will allow the companies to offer scientists “a faster path to discovery.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.